Pharmaceutical composition for combination therapy for preventing or treating cancer containing tumor-specific drug conjugate and anti-PD-L1 antibody as active ingredients
US11498946B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 11, 2020 |
| Grant date | Nov 15, 2022 |
| Priority date | — |
| Expiry date | Jan 13, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/54
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a pharmaceutical composition for combination therapy for preventing or treating cancer, which contains a first pharmaceutical ingredient containing a drug conjugate wherein an anticancer agent is bound at one end of an amphiphilic peptide represented by SEQ ID NO 1 and a poloxamer; and a second pharmaceutical ingredient containing an anti-PD-L1 antibody; as active ingredients. The pharmaceutical composition significantly inhibits cancer growth in in-vivo experiments and exhibits an effect of significantly enhancing immunotherapeutic effect by activating immune cells in cancerous tissues.In particular, the pharmaceutical composition for combination therapy according to the present disclosure has superior tumor accumulation efficiency and selectivity as compared to existing anticancer agents, and is very stable with little toxicity to normal tissues other than cancerous tissues.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.